Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.YGYNO.2005.11.020PMID 27954412
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

  2004cited by this paper
• Activity of docetaxel in paclitaxel-resistant ovarian cancer cells

  2004cited by this paper
• A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.

  2003cited by this paper
• A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

  2003cited by this paper
• Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

  2003cited by this paper
• Docetaxel in combination with carboplatin for chemo‐naive patients with epithelial ovarian cancer

  2002cited by this paper
• Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.

  2001cited by this paper
• What Is the “Best” Platinum: Cisplatin, Carboplatin, or Oxaliplatin?

  2001cited by this paper
• Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

  2000cited by this paper
• Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

  2000cited by this paper
• A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study.

  2000cited by this paper
• Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

  2000cited by this paper
• Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.

  1999cited by this paper
• Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group.

  1999cited by this paper
• Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion.

  1998cited by this paper
• Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview.

  1997cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• Peripheral neuropathy secondary to docetaxel (Taxotere)

  1996cited by this paper
• Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.

  1996cited by this paper
• Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer.

  1995cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• © 2001 Cancer Research Campaign

  year unknowncited by this paper

• Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer

  2020influential citation
• First-line chemotherapy for the treatment of women with epithelial ovarian cancer

  2019cites this paper
• Safe administration of docetaxel after weekly paclitaxel-induced acute pancreatitis

  2017cites this paper
• Gr upSM Platinum Agents , Taxanes and PARP Inhibitors : The Ovarian Cancer Drug Formulary and Molecular Mechanisms of Chemoresistance Emergence INTRODUCTION TO OVARIAN CANCER

  2016cites this paper
• Analysis on the Efficacy and Safety of the Patients with Advanced Ovarian Cancer

  2015cites this paper
• First-line chemotherapy for the treatment of women with epithelial ovarian cancer

  2014cites this paper
• Docetaxel and Carboplatin as Salvage Therapy for First-Relapsed, Platinum-Sensitive, Stage III/IV Advanced Ovarian Cancer

  2014cites this paper
• Docetaxel Obs Cancer BPL 01 2012

  2012cites this paper
• Docetaxel and Carboplatin (DC) for Ovarian Cancer

  2010cites this paper
• Combination of docetaxel-carboplatin for adjuvant chemotherapy of epithelial ovarian, primary peritoneal and fallopian tube cancers: a meta-analysis

  2010cites this paper
• Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer.

  2009cites this paper
• Recommandations pour la pratique clinique : Standards, Options : Recommandations 2008 pour la prise en charge des patientes atteintes de tumeurs épithéliales malignes de l’ovaire. Traitement médical de première ligne (rapport abrégé)

  2008cites this paper
• Recommandations pour la pratique clinique: Standards, Options: Recommandations 2007 pour la prise en charge des patientes atteintes de tumeurs épithéliales malignes de l’ovaire. Traitement chirurgical (rapport abrégé)

  2008cites this paper
• Docetaxel and ovarian cancer

  2007cites this paper